The research describes compelling preclinical findings providing the foundation for a planned Phase II clinical study, currently under review by health authorities in Italy

Ramat Gan, Israel, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the publication of research demonstrating that piclidenoson (IB-MECA), an orally administered A3 adenosine receptor agonist, corrects disease-associated cellular abnormalities and improves kidney protein reabsorption in preclinical models of Lowe syndrome. The findings were published in Signal Transduction and Targeted Therapy, a Nature Portfolio journal. https://doi.org/10.1038/s41392-026-03054-z

The study, entitled "An actionable GPCR restores phosphoinositide homeostasis and kidney function in Lowe syndrome," was led by researchers including Dr. Leopoldo Staiano and Prof. Maria Antonietta De Matteis at the Telethon Institute of Genetics and Medicine (TIGEM), with collaborators at the University of Naples Federico II and other international institutions.
 

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.